Paratek Completes Optinose Acquisition for $330 Million
Deal News | May 21, 2025 | EIN
Paratek Pharmaceuticals has announced the successful acquisition of Optinose, Inc., a deal valued at $330 million. This strategic acquisition aims to bolster Paratek's commercial portfolio, enhancing its standing as a specialty therapeutics company. The merger, offering Optinose shareholders $9 per share in cash and contingent value rights, promises additional payments conditioned on revenue achievements by Optinose's product, XHANCE. The acquisition was backed by financing from B-FLEXION Life Sciences, Novo Holdings, and Oaktree Capital Management. Paratek's leadership views this acquisition as a significant step toward achieving its long-term goal of expanding its specialty therapy offerings. Lazard and Skadden, Arps, Slate, Meagher & Flom LLP served as advisors to Paratek, while Optinose was advised by Evercore and Hogan Lovells US LLP.
Sectors
- Pharmaceuticals
- Healthcare
- Investment
Geography
- United States – The transaction involves U.S.-based Paratek Pharmaceuticals and Optinose, highlighting the focus on the U.S. pharmaceutical market.
- Europe – B-FLEXION Life Sciences, part of the financing group, has offices in Europe, indicating a European dimension to the investment.
Industry
- Pharmaceuticals – This sector is relevant as the article discusses Paratek Pharmaceuticals' acquisition of Optinose, both of whom are companies focused on developing pharmaceutical therapies.
- Healthcare – Healthcare is relevant because the acquisition involves specialty therapies addressing significant medical needs, impacting healthcare delivery.
- Investment – This sector is relevant due to the involvement of investment firms like B-FLEXION, Novo Holdings, and Oaktree in financing the acquisition.
Financials
- $330 million – Total acquisition cost for Optinose by Paratek Pharmaceuticals.
- $9 per share – Cash paid per share to Optinose shareholders.
- up to $5 per share – Contingent Value Rights (CVRs) for Optinose shareholders if revenue milestones are met.
- $150M and $225M – Revenue milestones required for CVR payouts from the sales of XHANCE by specific deadlines.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Paratek Pharmaceuticals, Inc. | Acquirer | Company | A pharmaceutical company focused on developing specialty therapies. |
| Optinose, Inc. | Target | Company | A pharmaceutical company known for its nasal drug-device XHANCE. |
| B-FLEXION Life Sciences | Financier | Company | An investment firm providing capital for the acquisition. |
| Novo Holdings A/S | Financier | Company | A life sciences investment company involved in financing the acquisition. |
| Oaktree Capital Management, L.P. | Debt Financier | Company | An investment manager providing debt financing for the acquisition. |
| Lazard | Financial Advisor | Company | Advised Paratek Pharmaceuticals on the acquisition. |
| Skadden, Arps, Slate, Meagher & Flom LLP | Legal Advisor | Company | Provided legal advisory services to Paratek Pharmaceuticals. |
| Evercore | Financial Advisor | Company | Served as a financial advisor to Optinose during the merger. |
| Hogan Lovells US LLP | Legal Advisor | Company | Provided legal counsel for Optinose. |
| Evan Loh, MD | CEO | Person | Chief Executive Officer of Paratek Pharmaceuticals. |